Vertex Pharmaceuticals Inc Quick Ratio (VRTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Vertex Pharmaceuticals Inc  (NASDAQ: VRTX)

Vertex Pharmaceuticals Inc's Quick Ratio

VRTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Vertex Pharmaceuticals Inc's Cash & cash equivalent grew by 8.36 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Vertex Pharmaceuticals Inc's Quick Ratio to 1.99, Quick Ratio remained below Vertex Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 290 other companies have achieved higher Quick Ratio than Vertex Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 617 to 1268.

Explain Quick Ratio?
How much Cash & cash equivalents VRTX´s has?
What are VRTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -4.84 % 2.57 % 8.32 % 12.64 % 16.67 %
Y / Y Cash & cash equivalent Change 23.02 % 16.86 % 8.05 % -3.64 % 10.13 %
Quick Ratio MRQ 1.99 1.87 1.71 1.4 1.54
VRTX's Total Ranking # 1268 # 617 # 824 # 1029 # 1075
Seq. Current Liabilities Change 1.48 % 0.5 % -13.72 % 8.14 % 9.39 %
Seq. Cash & cash equivalent Change 8.36 % 9.66 % 5.11 % -1.5 % 2.93 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 291
Healthcare Sector # 506
Overall Market # 1268


Quick Ratio Statistics
High Average Low
6.98 3.23 1.4
(Jun 30 2012)   (Sep 30 2025)




Financial Statements
Vertex Pharmaceuticals Inc's Current Liabilities $ 3,938 Millions Visit VRTX's Balance sheet
Vertex Pharmaceuticals Inc's Cash & cash equivalent $ 7,852 Millions Visit VRTX's Balance sheet
Source of VRTX's Sales Visit VRTX's Sales by Geography


Cumulative Vertex Pharmaceuticals Inc's Quick Ratio

VRTX's Quick Ratio for the trailling 12 Months

VRTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 4.5 % 10 % 9.26 % 3.11 % 2.34 %
Y / Y Cash & cash equivalent TTM Growth 10.98 % 7.66 % -10.93 % -25.88 % -35.51 %
Quick Ratio TTM 1.73 1.62 1.57 1.57 1.63
Total Ranking TTM # 3913 # 3900 # 2195 # 2955 # 2966
Seq. Current Liabilities TTM Growth -1.23 % 0.6 % 1.86 % 3.25 % 3.98 %
Seq. Cash & cash equivalent TTM Growth 5.54 % 4.1 % 1.97 % -0.94 % 2.38 %

Quick ratio ranking by company, industry and sector >> Back to VRTX Financial Strength Comparisons >> Go to Compare VRTX Quick Ratio to its Competitors

On the trailing twelve months basis VRTX Cash & cash equivalent grew by 23.02 % in Q2 2026 year on year, while Current Liabilities rose to $3,938 millions, this led to increase in in Vertex Pharmaceuticals Inc's Quick Ratio to 1.73, Quick Ratio remained below VRTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Vertex Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3900 to 3913.

Explain Quick Ratio?
How much Cash & cash equivalents VRTX´s has?
What are VRTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 892
Within the Market # 3913


trailing twelve months Quick Ratio Statistics
High Average Low
4.94 3.01 1.57
(Dec 31 2012)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions
Rani Therapeutics Holdings Inc   5.02 $ 53.391  Millions$ 10.638  Millions
Phio Pharmaceuticals Corp  4.99 $ 12.996  Millions$ 2.606  Millions
Immunic Inc   4.96 $ 155.098  Millions$ 31.260  Millions
Silo Pharma Inc  4.90 $ 5.227  Millions$ 1.066  Millions
Atossa Therapeutics Inc   4.81 $ 26.204  Millions$ 5.451  Millions
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions
Rein Therapeutics Inc   4.49 $ 43.627  Millions$ 9.709  Millions
Quantum Cyber N v   4.46 $ 13.415  Millions$ 3.005  Millions
Maia Biotechnology Inc   4.41 $ 27.596  Millions$ 6.258  Millions
Azitra Inc   4.40 $ 6.728  Millions$ 1.531  Millions
Cypherpunk Technologies Inc   4.39 $ 7.624  Millions$ 1.737  Millions
Rigel Pharmaceuticals Inc  4.35 $ 225.347  Millions$ 51.858  Millions
Biohaven Ltd   4.28 $ 267.866  Millions$ 62.658  Millions
Incannex Healthcare Inc  4.25 $ 67.711  Millions$ 15.940  Millions

Date modified: 2026-09-02T20:09:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.